ATE126534T1 - Cis-wirkung-repressionen-sequenzen, cis-wirkung- antirepressionen-sequenzen, vektoren, verfahren zur vorbereitung und anwendung. - Google Patents

Cis-wirkung-repressionen-sequenzen, cis-wirkung- antirepressionen-sequenzen, vektoren, verfahren zur vorbereitung und anwendung.

Info

Publication number
ATE126534T1
ATE126534T1 AT88304731T AT88304731T ATE126534T1 AT E126534 T1 ATE126534 T1 AT E126534T1 AT 88304731 T AT88304731 T AT 88304731T AT 88304731 T AT88304731 T AT 88304731T AT E126534 T1 ATE126534 T1 AT E126534T1
Authority
AT
Austria
Prior art keywords
sequences
repression
cis
cis action
vectors
Prior art date
Application number
AT88304731T
Other languages
English (en)
Inventor
William A Haseltine
Craig A Rosen
Joseph Gerald Sodroski
Ernest Terwilliger
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE126534T1 publication Critical patent/ATE126534T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT88304731T 1987-05-29 1988-05-25 Cis-wirkung-repressionen-sequenzen, cis-wirkung- antirepressionen-sequenzen, vektoren, verfahren zur vorbereitung und anwendung. ATE126534T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5662087A 1987-05-29 1987-05-29

Publications (1)

Publication Number Publication Date
ATE126534T1 true ATE126534T1 (de) 1995-09-15

Family

ID=22005604

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88304731T ATE126534T1 (de) 1987-05-29 1988-05-25 Cis-wirkung-repressionen-sequenzen, cis-wirkung- antirepressionen-sequenzen, vektoren, verfahren zur vorbereitung und anwendung.

Country Status (5)

Country Link
EP (1) EP0293181B1 (de)
JP (1) JPH0191786A (de)
AT (1) ATE126534T1 (de)
CA (1) CA1339733C (de)
DE (1) DE3854313D1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
ATE118247T1 (de) * 1988-09-27 1995-02-15 Dana Farber Cancer Inst Inc Vektor, der ein replikationskompetentes hiv-i- provirus und ein heterologes gen enthält.
DE69033975T2 (de) * 1989-01-23 2002-10-02 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Rekombinanttherapien für Infektionen und hyperproliferative Störungen
US5871958A (en) * 1989-05-25 1999-02-16 Duke University Mutant rev genes encoding transdominant repressors of HIV replication
US6251675B1 (en) * 1989-05-25 2001-06-26 Duke University Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication
JP3203599B2 (ja) * 1989-10-24 2001-08-27 カイロン コーポレイション 感染性タンパク質デリバリーシステム
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
JPH07501942A (ja) * 1991-11-29 1995-03-02 カイロン コーポレイション 抗ガン免疫療法用ベクター構成体
US5534408A (en) * 1993-09-24 1996-07-09 University Of Massachusetts Medical Center 2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
WO2000046403A2 (en) 1999-02-03 2000-08-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OFHEALT H AND HUMAN SERVICES Methods and reagents for molecular detection of hiv-1 groups m, n and o

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738922A (en) * 1984-05-25 1988-04-19 Dana Farber Cancer Institute Trans-acting transcriptional factors
DE3588134T2 (de) * 1984-12-24 1997-03-20 Genentech Inc Fusionen von AIDS-verwandten Polypeptiden
JPS63502161A (ja) * 1986-02-14 1988-08-25 アメリカ合衆国 ヒトt−細胞リンパ球指向性ウイルスタイプ3の複製を抑制するプラスミド

Also Published As

Publication number Publication date
JPH0191786A (ja) 1989-04-11
CA1339733C (en) 1998-03-17
EP0293181A1 (de) 1988-11-30
DE3854313D1 (de) 1995-09-21
EP0293181B1 (de) 1995-08-16

Similar Documents

Publication Publication Date Title
ATE126534T1 (de) Cis-wirkung-repressionen-sequenzen, cis-wirkung- antirepressionen-sequenzen, vektoren, verfahren zur vorbereitung und anwendung.
ATE102993T1 (de) Virale expressionsinhibitoren.
FI930658A0 (fi) Oligonukleotider foer modulering av effekten av cytomegalovirusinfektioner
FI934937A0 (fi) Sekvenser av HCV-genom foer diagnostisk och terapi
ATE189264T1 (de) Chimärisches oligonukleotid und dessen verwendung zur herstellung von nukleinsäure-transkripten
DE3875796D1 (de) Kombiniertes verfahren zur thermischen und chemischen behandlung von lignocellulosehaltiger biomasse und zur gewinnung von furfural.
DE69333529D1 (de) Pflanzenvirus-vektor, plasmid, methode der expression fremder gene und methode zur gewinnung obiger genprodukte
ATE16454T1 (de) Influenzavirus-vaccine, verfahren zu ihrer herstellung und verfahren zur vermehrung von influenzaviren.
DE59305227D1 (de) Verfahren zur Herstellung von 2-Methyl-1,4-butandiol und 3-Methyltetrahydrofuran
ATE337404T1 (de) Zur verleihung viraler resistenz an pflanzen geeignetes polyribozym und dieses polyribozym produzierende resistente pflanzen
SE7806087L (sv) Forfarande for rening av nukleotidsekvenser lempliga som syntetiseringsmall i bakterier, mikroorganism innefattande dylik nukleotidsekvens samt rekombinant dna-overforingsvektor innefattande dylik nukleotid
DE68913128D1 (de) Verfahren zur Herstellung von L-Alanin-Dehydrogenase und Mikroorganismusstamm des Genus Sporolactobacillus.
ATE184915T1 (de) Verfahren zur herstellung von vakzinen und ihre verwendung
DE68918563D1 (de) Protease, reverse Transcriptase und Endonuklease von Retroviren und Verfahren zur Herstellung dieser Enzyme.
DK0680333T3 (da) Forebyggelse og behandling af cytomegalovirus ved hjælp af aminopeptidase
ZA902436B (en) Purification of c.pseudotuberculosis toxin,and cloning and expression of toxin gene
ATE128188T1 (de) Menschliches gamma-interferon, verfahren zu seiner herstellung und seine verwendung.
DE3886234D1 (de) DNA-Sequenzen, Plasmide und Mikroorganismen sowie Verfahren zur Herstellung von Chinolinsäure.
ATE96029T1 (de) Zusammensetzung und verfahren zur behandlung von hepatitisvirusinfektionen unter verwendung von 1(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5- ethyluracil.
DE3850056D1 (de) Verfahren zur Regeneration von desaktivierten Mikroorganismen.
DE3883754D1 (de) Mittel zur prophylaxe und behandlung von viralen infektionskrankheiten.
ATE40648T1 (de) Behandlung von gegen interferon empfindliche krankheiten, verfahren und vorrichtung zur herstellung von -g(g)-interferon.
ATE9005T1 (de) Dns-sequenzen, rekombinante dns-molekuele und verfahren zur herstellung von dem menschlichen interferon-alpha aehnlichen polypeptiden.
DE69008959D1 (de) Verfahren zur Produktion von Protein mit Stämmen von Bacillus subtilis und Verfahren zur Vorbereitung dieser Stämme.
ATE56878T1 (de) Verfahren und zusammensetzung zur vorbeugung und behandlung von virus-infektionen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties